Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2020; 26(46): 7425-7435
Published online Dec 14, 2020. doi: 10.3748/wjg.v26.i46.7425
Published online Dec 14, 2020. doi: 10.3748/wjg.v26.i46.7425
Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report
Bin-Bin Huang, Li-Chun Han, Geng-Feng Liu, Guang-Li Gu, Shi-Quan Li, Lan Chen, Hui-Qin Wang, Xiao-Ping Lv, Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Xiao-Dan Lv, Ling-Ling Zhan, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Huang BB and Han LC drafted the table and the manuscript; Liu GF and Lv XD searched the relevant literature; Gu GL and Li SQ collected the data; Chen L and Wang HQ contributed to the design and revision of this study; Zhan LL reviewed the literature; Lv XP was the doctor in charge of the patient and revised the final manuscript.
Supported by the National Natural Science Foundation of China , No. 81860104 and 81460114 ; the Natural Science Foundation of Guangxi Zhuang Autonomous Region , No. 2017GXNSFAA198299 ; the Development and Application of Medical and Health Appropriate Technology Project in Guangxi Zhuang Autonomous Region , No. S2018049 ; the Youth Science Foundation of Guangxi Medical University , No. GXMUYSF201913 and GXMUYSF201908 ; and the Self-financing Project of Health Commission of Guangxi Zhuang Autonomous Region , No. Z20200398 .
Informed consent statement: Informed written consent was obtained from the patient for publication of this report.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xiao-Ping Lv, MM, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. lxxp58@hotmail.com
Received: July 28, 2020
Peer-review started: July 28, 2020
First decision: September 30, 2020
Revised: October 11, 2020
Accepted: November 4, 2020
Article in press: November 4, 2020
Published online: December 14, 2020
Processing time: 138 Days and 23 Hours
Peer-review started: July 28, 2020
First decision: September 30, 2020
Revised: October 11, 2020
Accepted: November 4, 2020
Article in press: November 4, 2020
Published online: December 14, 2020
Processing time: 138 Days and 23 Hours
Core Tip
Core Tip: Few cases of ulcerative colitis have dermatomyositis (DM) as complication. DM may be a less frequent extraintestinal manifestation of ulcerative colitis. Infliximab is effective in the treatment of ulcerative colitis in patients with autoimmune disease or poor hormone response.